JACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated through exposure to tuned laser irradiation. TNF-α is an inflammatory cytokine which has been identified as a major contributor to Alzheimer's Disease, and recently has been linked to obesity.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation and a board certified attending neurologist remarked, 'TNF-α has been shown to be a significant contributor to the incidence of Alzheimer's disease. Studies have shown that neuroinflammation promotes the pathological process which leads to Alzheimer's Disease,,. Drugs designed to inhibit neuroinflammation are limited in their effectiveness because they are inefficient at traversing the blood-brain barrier. Our extracorporeal elimination of the TNF-α inflammatory cytokine from cerebral spinal fluid could lead to a completely new approach to the treatment of Alzheimer's Disease. A reduction in the amount of TNF-α by over 80% in such a short time is a truly remarkable achievement.'
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, 'This is the latest step in our march towards finding effective treatments for PTSD, CTE and Alzheimer's Disease. We earlier reported on our successful elimination of Phosphorylated Tau from CSF, the primary building block of neurofibrillary tangles associated with Alzheimer's Disease, and Interleukin 6 (IL-6), another inflammatory cytokine associated with cognitive decline.'
'Our next steps in our research program will address the elimination from, or the regulation of levels of several other inflammatory cytokines, proteins and glutamate in CSF, which have been linked to the onset and progression of Alzheimer's disease, other neurodegenerative diseases and obesity. Our longer term objective is to continue to focus on the eradication of the remaining pathogens from CSF and blood plasma related to Alzheimer's Disease, Parkinson's Disease, Lou Gehrig's Disease, Epilepsy and Obesity.'
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed sixteen provisional, utility or PCT patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis. The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.'
Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:1200-1205. [PMC free article] [PubMed] [Google Scholar]
 McCaulley ME, Grush KA. Alzheimer's disease: exploring the role of inflammation and implications for treatment. Int J Alzheimers Dis. 2015;2015:515248. [PMC free article] [PubMed] [Google Scholar]
SOURCE: Halberd Corporation
View source version on accesswire.com: